Saniona AB stock analysis
Want to see SE:SANION full AI Analyst Report?
Saniona AB (SANION) Stock Price & Analysis
SANION Stock Chart & Stats
- Day’s Range
- SEK 11.85 - SEK 12.34
- 52-Week Range
- SEK 8.53 - SEK 28.30
- Previous Close
- SEK 12.00
- Volume
- N/A
- Average Volume (3M)
- 421.00K
- Market Cap
- SEK 1.66B
- Enterprise Value
- SEK 1.32B
- Total Cash (Recent Filing)
- SEK 486.31M
- Total Debt (Recent Filing)
- SEK 0
- Price to Earnings (P/E)
- 9.0
- Beta
- 0.36
- Next Earnings
- Nov 26, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
A debt-free balance sheet and substantial equity base reduce fixed financial obligations and improve Saniona’s ability to withstand operating volatility. This strengthens financial flexibility for advancing drug candidates, funding research, or pursuing partnerships without near-term pressure from lenders.
Strong Profitability Turnaround
The shift from heavy losses in 2021–2023 to strong 2025 and TTM profitability indicates materially improved earnings power. If supported by recurring business activity, these margins can provide internal funding for development programs and improve resilience across the next several quarters.
Positive Cash Generation
Positive operating and free cash flow across the latest reported periods is a meaningful strength for a development-stage biotechnology company. Cash generation can reduce reliance on external financing and support ongoing operations, although its durability depends on more consistent revenue and earnings.
Bears Say
Severe Revenue Volatility
Sharp swings in revenue weaken visibility into Saniona’s underlying earning capacity and make current profitability harder to forecast. Such volatility is particularly important for a biotechnology model where licensing or milestone-related income can be uneven, potentially reducing confidence in durable growth.
Weak Cash Conversion
Free cash flow below net income suggests that reported earnings are not converting fully into cash, while the year-to-year swings indicate uneven cash-generation quality. This can constrain the reliability of internally funded investment and make future cash resources more dependent on operating variability.
Recent Capital-structure Instability
The current balance sheet is conservative, but the recent history of leverage and negative equity shows that Saniona’s capital structure has not been consistently stable. A recurrence of financial stress could weaken funding flexibility and make long-term development plans more sensitive to business volatility.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
What is Saniona AB’s market cap?
When is Saniona AB’s upcoming earnings report date?
How were Saniona AB’s earnings last quarter?
Is Saniona AB overvalued?
Does Saniona AB pay dividends?
What is Saniona AB’s EPS estimate?
How many shares outstanding does Saniona AB have?
What happened to Saniona AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Saniona AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Feldthus
- Employees
- 44
- Website
- www.saniona.com
- Address
- Murervangen 42, Glostrup, CD, 2600, DK
Saniona AB (SANION) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 3 | 7 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 10 | 0 | 2 |
